Advertisement
- China
- /
- Healthcare Services
- /
- SHSE:600211
Tibet Rhodiola Pharmaceutical Holding Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Tibet Rhodiola Pharmaceutical Holding (SHSE:600211) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥2.81b (down 11% from FY 2023).
- Net income: CN¥1.05b (up 31% from FY 2023).
- Profit margin: 38% (up from 26% in FY 2023). The increase in margin was driven by lower expenses.
- EPS: CN¥3.26 (up from CN¥2.49 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tibet Rhodiola Pharmaceutical Holding EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 18%. Earnings per share (EPS) exceeded analyst estimates by 2.5%.
Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Healthcare industry in China.
Performance of the Chinese Healthcare industry.
The company's shares are up 1.8% from a week ago.
Risk Analysis
You should learn about the 1 warning sign we've spotted with Tibet Rhodiola Pharmaceutical Holding.
Valuation is complex, but we're here to simplify it.
Discover if Tibet Rhodiola Pharmaceutical Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SHSE:600211
Tibet Rhodiola Pharmaceutical Holding
Tibet Rhodiola Pharmaceutical Holding Co.
Solid track record with excellent balance sheet and pays a dividend.
Market Insights
Advertisement
Weekly Picks
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.886.2% undervalued
58 followersusers have followed this narrative
5 commentsusers have commented on this narrative
25 likesusers have liked this narrative
TO
Tokyo on LVMH Moët Hennessy - Louis Vuitton Société Européenne ·
EU#4 - Turning Heritage into the World’s Strongest Luxury Empire
Fair Value:€750.0428.3% undervalued
5 followersusers have followed this narrative
1 commentusers have commented on this narrative
9 likesusers have liked this narrative
WE
WealthAP on Alphabet ·
The "Easy Money" Is Gone: Why Alphabet Is Now a "Show Me" Story
Fair Value:US$386.4316.1% undervalued
66 followersusers have followed this narrative
1 commentusers have commented on this narrative
20 likesusers have liked this narrative
Recently Updated Narratives
PI
PittTheYounger on Delta Air Lines ·
Delta loses shine after warning of falling travel demand, but still industry leader
Fair Value:US$63.2118.7% overvalued
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
RA
Ravedigga on Defence Holdings ·
Project Ixian Accelerated Rollout will Drive Valuation Expansion to £0.0150.
Fair Value:UK£0.01516.7% undervalued
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
TO
Tokyo on Siemens ·
EU#5 - From Industrial Giant to the Digital Operating System of the Real World
Fair Value:€319.519.1% undervalued
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
OO
OOO97 on Neo Performance Materials ·
Undervalued Key Player in Magnets/Rare Earth
Fair Value:CA$25.3317.8% undervalued
76 followersusers have followed this narrative
0 commentsusers have commented on this narrative
20 likesusers have liked this narrative
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.886.2% undervalued
58 followersusers have followed this narrative
5 commentsusers have commented on this narrative
25 likesusers have liked this narrative
BL
BlackJesus on Adobe ·
The Strategic Revaluation of Adobe: A Critical Analysis of Market Sentiment
Fair Value:US$46042.0% undervalued
34 followersusers have followed this narrative
2 commentsusers have commented on this narrative
22 likesusers have liked this narrative
Trending Discussion
KA
Kalibrator on Ubisoft Entertainment ·
As a gamer, I would not touch this company now. They are hated by the community and have been releasing major flops on their AAA games during the last 5 years (for good reasons). It is true that the valuation is ridiculously low compared to what the licenses are worth, but if the trend continues the value of those will also decline. Management needs to almost make a 180° turnaround to get things right. I agree that a take-private deal before it is too late might be the best option for an investor entering today. We might also see a split sales of the different studios. It is a very risky play, but potentially with high reward.
1
|0